Oscient Pharmaceuticals Corporation Receives Paragraph IV Certification Notice for ANTARA

WALTHAM, Mass.--(BUSINESS WIRE)--Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) today announced that the Company and its licensor, Ethypharm SA, have received notice of a Paragraph IV certification on behalf of Lupin Limited, advising of the submission of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for ANTARA® (fenofibrate) capsules, 130 and 43 mg doses.